Form 4/A for ANTX AN2 Therapeutics, Inc.
Accepted 2024-03-29 00:00:00 ET · period of report 2024-03-15 · accession 0001610717-24-000191 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2024-03-29 | 2024-03-15 | ANTX | Easom Eric | CEO, Dir | A - Grant | $0.00 | +99.0K | 101.1K | +4,648% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-15 | A | A | 99,000 | $0.00 | 101,130 | D | — | — | (F1) Previously reported on a Form 4 filed on March 18, 2024. As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date. |